Pharmacology in treatment of vasculitis
dc.contributor.advisor | Pórszász, Róbert | |
dc.contributor.advisordept | Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | hu_HU |
dc.contributor.author | Nguyen, Thanh Tung | |
dc.contributor.department | DE--Általános Orvostudományi Kar | hu_HU |
dc.contributor.opponent | Szentmiklósi, József András | |
dc.contributor.opponent | Drimba, László | |
dc.contributor.opponentdept | Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | hu_HU |
dc.contributor.opponentdept | Kenézy Kórház Központi Aneszteziológiai és Intenzív Terápiás Osztály | hu_HU |
dc.date.accessioned | 2019-01-30T09:15:58Z | |
dc.date.available | 2019-01-30T09:15:58Z | |
dc.date.created | 2018 | |
dc.description.abstract | The type of vasculitis and the extent of organ involvement guide following treatment. The goals of therapy are 3-fold: To achieve disease remission, to prevent disease recurrence, and to minimize toxicity associated with drug therapy. . In the end, treatment is not without cost, and a high percentage of those surviving will have considerable morbidity related either to the underlying condition or to the treatment itself. New, more specific treatments are under investigation, and have the potential to improve this even further and perhaps reduce the associated morbidity. | hu_HU |
dc.description.course | általános orvos | hu_HU |
dc.description.courselang | angol | hu_HU |
dc.description.degree | egységes, osztatlan | hu_HU |
dc.format.extent | 36 | hu_HU |
dc.identifier.uri | http://hdl.handle.net/2437/263361 | |
dc.language.iso | en | hu_HU |
dc.subject | pharmacology in vasculitis | hu_HU |
dc.subject.dspace | DEENK Témalista::Orvostudomány | hu_HU |
dc.title | Pharmacology in treatment of vasculitis | hu_HU |